Last reviewed · How we verify
AIC100 CAR T Cells
Chimeric antigen receptor T cells targeting CD19
Chimeric antigen receptor T cells targeting CD19 Used for Relapsed or refractory B-cell lymphoma.
At a glance
| Generic name | AIC100 CAR T Cells |
|---|---|
| Also known as | AIC100 |
| Sponsor | AffyImmune Therapeutics, Inc. |
| Drug class | CAR T cell therapy |
| Target | CD19 |
| Modality | Biologic |
| Therapeutic area | Oncology |
| Phase | Phase 1 |
Mechanism of action
AIC100 CAR T Cells are genetically modified T cells that target and kill cancer cells expressing CD19.
Approved indications
- Relapsed or refractory B-cell lymphoma
Common side effects
- Cytokine release syndrome
- Neutropenia
- Anemia
- Thrombocytopenia
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- AIC100 CAR T Cells CI brief — competitive landscape report
- AIC100 CAR T Cells updates RSS · CI watch RSS
- AffyImmune Therapeutics, Inc. portfolio CI